Oxyglobin Solution

Oxyglobin Solution


For the treatment of all-cause Canine Anemia

Oxyglobin® [hemoglobin glutamer - 200 (bovine)], or HBOC-301 is the first and only oxygen therapeutic to receive marketing clearance from the U.S. FDA and the European Commission for veterinary use. The product is indicated for the treatment of canine anemia regardless of the cause. Anemia is a potentially life-threatening condition that affects millions of dogs each year.

Oxyglobin was introduced to U.S. veterinarians in 1998. Since that time, the product has been used by thousands of veterinarians nationwide to treat various critical conditions.

Other than a blood transfusion, Oxyglobin is the only treatment that provides immediate relief from the clinical signs of anemia in dogs. The most common side effects of Oxyglobin are transient discoloration of skin, mucous membranes and urine. Circulatory overload is an uncommon but important side effect. Other adverse reactions such as vomiting and melena (dark colored feces) have occurred. Based on data from more than 800 case studies nationwide, Oxyglobin is being used both as an oxygen carrying fluid therapy and as an alternative to red blood cell transfusion (e.g., massive blood loss, immune-mediated hemolytic anemia, etc.).

Tissue Oxygenation

Oxyglobin is a sterile, intravenously administered solution consisting of chemically stabilized hemoglobin (the protein that carries oxygen) in a balanced salt solution. Unlike blood, it does not contain red blood cells. Instead, it contains cross-linked hemoglobin molecules (several tetramers bound together) that circulate in plasma and immediately transport oxygen to tissues upon infusion.

product animations

 

Last Update: November 2012

Laboratory Interference Reference Guide

For individuals interested in the impact of hemoglobin based oxygen carriers on laboratory assays.

Learn More
 
Oxyglobin® Solution Use Video

View an Oxyglobin® Solution video case study of a dog with thrombocytopenia and IMHA being administered Oxyglobin.